Form 4: ARWR CMO Sells $200K in Stock via 10b5-1 Plan

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock for $200,000 through a pre-arranged 10b5-1 trading plan.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), reported the sale of common stock.
• A total of 10,000 shares were sold across two transactions on August 13, 2025, and August 15, 2025.
• All shares were sold at a price of $20.00 per share, totaling $200,000 in proceeds.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person.
• Following these transactions, James C. Hamilton beneficially owns 262,122 shares of common stock, which includes previously reported shares underlying Restricted Stock Units subject to vesting conditions.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale under a 10b5-1 plan, which is a routine disclosure and does not inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Disclosure of insider selling, even if pre-scheduled, provides transparency on management's holdings and can sometimes lead to questions about confidence, though 10b5-1 plans mitigate this concern.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, James C. Hamilton, Chief Medical Officer